+

AR132497A1 - Combination of amorphous OBICETRAPIB and SGLT2 inhibitor - Google Patents

Combination of amorphous OBICETRAPIB and SGLT2 inhibitor

Info

Publication number
AR132497A1
AR132497A1 ARP240101021A ARP240101021A AR132497A1 AR 132497 A1 AR132497 A1 AR 132497A1 AR P240101021 A ARP240101021 A AR P240101021A AR P240101021 A ARP240101021 A AR P240101021A AR 132497 A1 AR132497 A1 AR 132497A1
Authority
AR
Argentina
Prior art keywords
obicetrapib
sglt2 inhibitor
disorder
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
ARP240101021A
Other languages
Spanish (es)
Inventor
Michael Harvey Davidson
Marc Ditmarsch
Johannes Jacob Pieter Kastelein
Sheng Cui
Andreas Ren Rtheli
Christopher J Borths
Muneki Kishida
Original Assignee
Newamsterdam Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newamsterdam Pharma B V filed Critical Newamsterdam Pharma B V
Publication of AR132497A1 publication Critical patent/AR132497A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona en la presente una composición farmacéutica que comprende sal de calcio amorfa de obicetrapib y al menos un inhibidor de SGLT2, o una sal farmacéuticamente aceptable del mismo. También se proporcionan formas de dosificación que incluyen la misma. En algunas formas de forma de realización, la forma de dosificación es una forma de dosificación sólida, como un comprimido. También se proporcionan procesos para la preparación de formulaciones de dosis fijas de obicetrapib cálcico amorfo y un inhibidor de SGTL2, y métodos para utilizar las mismas en el tratamiento de un trastorno metabólico (por ejemplo, diabetes de tipo 2) o cardiometabólico. También se proporcionan métodos para tratar o prevenir un trastorno metabólico o un trastorno cardiometabólico en un sujeto que tiene o está en riesgo de desarrollar un trastorno metabólico o un trastorno cardiometabólico, que comprenden: administrar una cantidad terapéuticamente eficaz de obicetrapib, o una sal farmacéuticamente aceptable del mismo; y una cantidad terapéuticamente eficaz de al menos un inhibidor de SGLT2, o una sal farmacéuticamente aceptable del mismo.Provided herein is a pharmaceutical composition comprising obicetrapib amorphous calcium salt and at least one SGLT2 inhibitor, or a pharmaceutically acceptable salt thereof. Also provided are dosage forms including the same. In some embodiments, the dosage form is a solid dosage form, such as a tablet. Also provided are processes for preparing fixed-dose formulations of obicetrapib amorphous calcium and an SGLT2 inhibitor, and methods of using the same in the treatment of a metabolic (e.g., type 2 diabetes) or cardiometabolic disorder. Also provided are methods of treating or preventing a metabolic disorder or a cardiometabolic disorder in a subject having or at risk of developing a metabolic disorder or a cardiometabolic disorder, comprising: administering a therapeutically effective amount of obicetrapib, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of at least one SGLT2 inhibitor, or a pharmaceutically acceptable salt thereof.

ARP240101021A 2023-04-24 2024-04-23 Combination of amorphous OBICETRAPIB and SGLT2 inhibitor AR132497A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363497891P 2023-04-24 2023-04-24

Publications (1)

Publication Number Publication Date
AR132497A1 true AR132497A1 (en) 2025-07-02

Family

ID=91129723

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101021A AR132497A1 (en) 2023-04-24 2024-04-23 Combination of amorphous OBICETRAPIB and SGLT2 inhibitor

Country Status (3)

Country Link
AR (1) AR132497A1 (en)
TW (1) TW202446389A (en)
WO (1) WO2024226537A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4551567A1 (en) * 2022-07-05 2025-05-14 NewAmsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148384A0 (en) 1999-08-31 2002-09-12 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
WO2002044192A1 (en) 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
DE60138768D1 (en) 2000-12-28 2009-07-02 Kissei Pharmaceutical Glucopyranosylpyrrazole derivatives and their use in medicines
BR0308653A (en) 2002-03-22 2005-02-15 Kissei Pharmaceutical Glycopyranosyloxybenzyl benzene derivative crystals
DE10231370B4 (en) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophene glycoside derivatives, medicaments containing these compounds and methods of making these medicaments
EP1980560B1 (en) 2003-03-14 2011-05-25 Astellas Pharma Inc. C-glycoside derivatives for the treatment of diabetes
EP2896397B2 (en) 2003-08-01 2020-10-07 Mitsubishi Tanabe Pharma Corporation Novel compounds having inhibitory activity against sodium-dependant glucose transporter
WO2005092877A1 (en) 2004-03-16 2005-10-06 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
UA90269C2 (en) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Tetrahydroquinoline derivatives and a process for preparing the same
US7687469B2 (en) 2004-12-16 2010-03-30 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
UA91546C2 (en) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Crystalline form of 1-chloro-4-(я-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
AR056195A1 (en) 2005-09-15 2007-09-26 Boehringer Ingelheim Int PROCEDURES TO PREPARE DERIVATIVES OF (ETINIL-BENCIL) -BENZENE REPLACED GLUCOPYRANOSIL AND INTERMEDIATE COMPOUNDS OF THE SAME
CA2635838A1 (en) 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
WO2007140191A2 (en) 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TWI403516B (en) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
US8039441B2 (en) 2006-08-15 2011-10-18 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
US8283326B2 (en) 2006-10-27 2012-10-09 Boehringer Ingelheim International Gmbh Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
AR063569A1 (en) 2006-11-06 2009-02-04 Boehringer Ingelheim Int DERIVATIVES OF BENZIL- BENZONITRILE SUBSTITUTED WITH GLUCOPYRANOSIL MEDICINES CONTAINING COMPOUNDS OF THIS TYPE ITS USE OR PROCEDURE FOR MANUFACTURING
UY30730A1 (en) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp CRYSTAL FORM OF HEMIHYDRATE 1- (B (BETA) -D-GLUCOPYRANOSIL) -4-METHYL-3- [5- (4-FLUOROPHENYL) -2-TIENYLMETHYL] BENZENE
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
EA020209B1 (en) 2007-09-10 2014-09-30 Янссен Фармацевтика Н.В. Process for the preparation of compounds useful as inhibitors of sodium-dependent glucose transporter
CN104906582A (en) * 2009-02-13 2015-09-16 勃林格殷格翰国际有限公司 Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof
WO2014008374A2 (en) * 2012-07-06 2014-01-09 Thetis Pharmaceuticals Llc Combination therapies comprising metformin salts and antihyperglycemia agents or antihyperlipidemia agents
EP3708158A1 (en) * 2019-03-11 2020-09-16 Hartis-Pharma SA Allosteric regulators of hemoglobin useful in the treatment of sickle cell trait

Also Published As

Publication number Publication date
WO2024226537A1 (en) 2024-10-31
TW202446389A (en) 2024-12-01
WO2024226537A9 (en) 2025-03-27

Similar Documents

Publication Publication Date Title
ECSP20069416A (en) TREATMENT OF SUPURATIVE HYDRADENITIS USING JAK INHIBITORS
CL2021001810A1 (en) Combination of dextromethorphan and bupropion for the treatment of depression
MX2022014313A (en) FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS WITH CONTROLLED ABSORPTION PROFILE.
MX2015017307A (en) USE OF PRIDOPIDINE IN HIGH DOSE FOR THE TREATMENT OF HUNTINGTON'S DISEASE.
AR045710A1 (en) USE OF TNF ALFA INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM FOR LOW DOSE TREATMENT
AR105712A1 (en) QUICK ACTION INSULIN COMPOSITIONS
CO2022013777A2 (en) Use of agents for the treatment of respiratory conditions
ECSP045430A (en) COMBINATION THERAPY FOR CANCER TREATMENT
IL300151A (en) Combinations for cancer treatment
AR060089A1 (en) PAIN TREATMENT
AR048431A1 (en) GALENIC FORMULATIONS OF ORGANIC COMPOUNDS
ES2570401T3 (en) Methods of treatment using single doses of oritavancin
UA107578C2 (en) COMBINED DIABETES THERAPY
BRPI0415953A (en) oral controlled release dosage formulation, method of treating a disorder, set of controlled release dosage forms and method for administering the formulation
AR039164A1 (en) VENLAFAXINE SALTS OF LOW WATER SOLUBILITY
AR132497A1 (en) Combination of amorphous OBICETRAPIB and SGLT2 inhibitor
EA202190544A1 (en) APPLICATION OF RILUZOL TABLETS DISPOSING IN THE ORAL CAVITY FOR THE TREATMENT OF DISEASES
AR119033A1 (en) METHODS FOR TREATING VIRUS-ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS
AR046036A1 (en) RISEDRONATE COMPOSITIONS AND METHODS FOR USE
AR127247A1 (en) CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS
MX2025005378A (en) Methods for the treatment of cardiovascular disease
CL2021000627A1 (en) Pharmaceutical compositions suitable for joint release and their use in the treatment of joint pain
CO2025007025A2 (en) Oral compactable formulations of ibutamoren
MX2024008330A (en) Obicetrapib and sglt2 inhibitor combination
MX2024010392A (en) Remibrutinib for use in the treatment of hidradenitis suppurativa.
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载